References
- Correale P, Tagliaferri P, Fioravanti A, Del Vecchio MT, Remondo C, Montagnani F, et al.. Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine+FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial). Clin Cancer Res. 2008;14:4192–9.
- Correale P, Fioravanti A, Bertoldi I, Montagnani F, Miracco C, Francini G. Occurrence of autoimmunity in a long-term survivor with metastatic colon carcinoma treated with a new chemo-immunotherapy regimen. J Chemother. 2008;20:278–81.
- Correale P, Messinese S, Caraglia M, Marsili S, Piccolomini A, Petrioli R, et al.. A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma. Br J Cancer. 2004;90:1710–4.
- Correale P, Cusi MG, Tsang KY, Del Vecchio MT, Marsili S, Placa ML, et al.. Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients. J Clin Oncol. 2005;23:8950–8.
- Fox RI. Sjögren’s syndrome. Lancet. 2005;366:321–31.
- Li X, Li X, Qian L, Wang G, Zhang H, Wang X, et al.. T regulatory cells are markedly diminished in diseased salivary glands of patients with primary Sjögren's syndrome. J Rheumatol. 2007;34:2438–45.
- Correale P, Montagnani F, Miano S, Sciandivasci A, Pascucci A, Petrioli R, et al.. Biweekly triple combination chemotherapy with gemcitabine, oxaliplatin, levofolinic acid and 5-fluorouracil (GOLF) is a safe and active treatment for patients with inoperable pancreatic cancer. J Chemother. 2008;20:119–25.